Unlocking The Clinical Outcomes Of Venetoclax In Leukemia: Orr, Cr, Mrd, Rfs, And Os
Venetoclax, a targeted therapy for leukemia, boasts a high overall response rate (ORR), with many patients achieving complete response (CR). Minimal residual disease (MRD) monitoring provides valuable prognostic information, indicating a deeper remission. Relapse-free survival (RFS) and overall survival (OS) are essential long-term outcomes, influenced by prognostic factors and treatment-related mortality (TRM). Understanding these outcomes…